| Project/Area Number |
05671079
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Kyoto Prefectural University of Medicine |
|---|
Principal Investigator |
KOJIMA Osamu KYOTO PREFECTURAL UNIVERSITY OF MEDICINE MEDICAL DEPARTMENT ASSISTANT PROFFESOR, 医学部, 助教授 (30117882)
|
|---|
| Project Period (FY) |
1993 – 1994
|
| Project Status |
Completed (Fiscal Year 1994)
|
| Budget Amount *help |
¥2,100,000 (Direct Cost: ¥2,100,000)
Fiscal Year 1994: ¥800,000 (Direct Cost: ¥800,000)
Fiscal Year 1993: ¥1,300,000 (Direct Cost: ¥1,300,000)
|
|---|
| Keywords | Scirrhous-type gastric cancer / Zoladex / LH-RH analogue / Endocrine-therapy / Estrogen receptor / Estrogen / KATO-III / エストロジエン / ゴナドトロピン |
|---|
| Research Abstract |
In order to improving prognosis of scirrhous type gastric cancer patients, we studied new endocrine therapy using LH-RH analogue (Zoladex). 1. Studies on inhibition of cancer cell line. It was found that the proliferation of the KATO-III cell line (estrogenreceptor-positivecell) was inhibited by 1x10^<-6>-10^<-7>M Zoladex with E_2. On the other hand, the proliferation of MKOI (ER negative cell) was not inhibited by 1x10^<-6>-10^<-7>M Zoladex with E_2. In nude mouse bearing xenograft tumor, Kato-III cells were inhibited by Zoladex. In patients with scirrhous-type gastric cancer, the levels of serum estrogen decreased after administration of Zoladex. However, it was not clear that the size of scirrhous-type gastric cancer decreased by Zoladex. In the present study, it can be concluded that Zoladex might be useful for the treatment of scirrhous-type gastric cacer.
|
